Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$173.61 USD

173.61
4,066,881

+1.29 (0.75%)

Updated Jul 22, 2024 04:00 PM ET

Pre-Market: $173.60 -0.01 (-0.01%) 9:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (186 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Arpita Dutt headshot

4 Drug Stocks in Focus this World Hepatitis Day

Does the hepatitis C virus (HCV) market still hold potential for companies like Gilead (GILD)?

    AbbVie (ABBV) Tops Q2 Earnings and Revenue

    AbbVie's (ABBV) second-quarter 2017 earnings surpassed estimates with revenue marginally beating the same. Sales of its??? lead marketed drug Humira also increased compared to year ago figure

      Jeffrey Hymen headshot

      Friday's Earnings Reports To Watch: XOM, CVX, MRK, ABBV

      The Zacks Earnings Calendar lists each company that is expected to report earnings on any given calendar date, making it a useful organizational tool for any investor.

        Pharma Stocks to Watch for Earnings on Jul 28: ABBV, MRK

        Total earnings for these 171 index members were up 8.8% from the year-ago quarter on a 3.4% improvement in revenues. Let's see how things are shaping up for the announcements.

          Vertex (VRTX) Q2 Earnings Top on Solid Cystic Fibrosis Sales

          Vertex Pharmaceuticals Incorporated's (VRTX) Q2 results were encouraging, as it topped earnings and revenues expectations backed by higher sales of both its CF drugs.

            Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up

            Gilead Sciences' (GILD) better-than-expected second-quarter results boosted investors sentiments.

              Biogen (BIIB) Tops Q2 Earnings & Sales, Spinraza Sales Up

              Biogen Inc. (BIIB) surpassed expectations both for earnings and sales in the second quarter of 2017. The MS drugmaker also raised its revenue guidance for 2017 on the back of strong Spinraza sales.

                Sweta Killa headshot

                Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs

                Though the healthcare sector is expected to post an earnings decline and has a dismal Rank, some surprises may well be in the cards, suggesting upside for healthcare ETFs.

                  AbbVie Inc's. (ABBV) Q2 Earnings: Disappointment in Store?

                  AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q2 despite a negative Earnings ESP posing a threat to the stock.

                    Is Gilead (GILD) Poised for a Beat This Earnings Season?

                    Strong performance by HIV and other antiviral products is likely to drive Gilead Sciences Inc.'s (GILD) second-quarter 2017 results.

                      Gilead's HCV Portfolio Receives a Boost With Vosevi Approval

                      Gilead's (GILD) HCV portfolio received a boost with the FDA's approval of its once-daily HCV regimen, Vosevi.

                        Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?

                        At Biogen's (BIIB) Q2 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in Q2.

                          Perrigo Company Gets FDA Approval for Generic Topical Gel

                          Perrigo Company plc (PRGO) receives approval from the FDA for generic version of Androgel Topical Gel, for replacement therapy in males.

                            Repros' Proellex Stays on Partial Clinical Hold, Shares Fall

                            Repros Therapeutics Inc. (RPRX) announced that its pipeline candidate Proellex which is being evaluated for uterine fibroids will remain on partial clinical hold.

                              J&J (JNJ) Gets FDA Nod for Psoriasis Drug -- Guselkumab

                              Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved its pipeline candidate guselkumab for the treatment of moderate-to-severe plaque psoriasis. The drug will be marketed by the trade name of Tremfya.

                                The Zacks Analyst Blog Highlights: Boeing, AbbVie and U.S. Bancorp

                                The Zacks Analyst Blog Highlights: Boeing, AbbVie and U.S. Bancorp

                                  Can Novartis (NVS) Spring a Surprise This Earnings Season?

                                  Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report second-quarter 2017 results on Jul 18.

                                    Mark Vickery headshot

                                    Top Stock Reports for Boeing, AbbVie & U.S. Bancorp

                                    Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), AbbVie (ABBV), and U.S. Bancorp (USB).

                                      Amgen Gets FDA Nod to Broaden Leukemia Drug Blincyto's Label

                                      Amgen Inc. (AMGN) announced that its supplemental biologics license application (sBLA) to convert accelerated approval for leukemia drug Blincyto to regular approval has been approved by the FDA.

                                        Sweta Killa headshot

                                        IPO Market Back On Track: ETFs to Tap

                                        After several lackluster quarters, the U.S. IPO market gained momentum in the second quarter of 2017.

                                          Roche (RHHBY) Announces Positive Data on Hemophilia A Drug

                                          Roche Holdings AG (RHHBY) announced positive data from the phase III study, HAVEN 1, on hemophilia A candidate emicizumab.

                                            Novartis' Cosentyx Superior to Stelara in Psoriasis Study

                                            Novartis' (NVS) psoriasis drug Cosentyx got a label update from the Committee for Medicinal Products for Human Use (CHMP) in the EU,

                                              Bristol-Myers Gets FDA Nod for Orencia's Label Expansion

                                              Bristol-Myers Squibb Company (BMY) announced that the FDA has approved Orencia for treatment of adults with active psoriatic arthritis (PsA).

                                                Galapagos-Gilead Begin Phase II Study on Uveitis Candidate

                                                Galapagos NV (GLPG) has announced initiation of a new phase II study, evaluating its lead pipeline candidate filgotinib for treatment of adult patients with non-infectious uveitis.

                                                  Bayer Starts Phase III Study for Uterine Fibroids' Candidate

                                                  Bayer Aktiengesellschaft (BAYRY) announced that it has enrolled the first patient in a phase III study ASTEROID which will evaluate vilaprisan in women suffering from uterine fibroids.